For Healthcare Professionals: Clinical Updates in Leukemias

Resources

We provide a collaborative team approach to the management of approximately 350 new patients with leukemia annually. A primary doctor closely coordinates the care of hematologists, medical and radiation oncologists, bone marrow and stem cell specialists, pathologists, and others. The team meets weekly to discuss and update each patient’s treatment plan. Our many clinical trials incorporate innovative therapies for various types of leukemias. We are recognized as leaders in immunotherapy and the development of novel drug strategies for a number of leukemias.

Phase I Clinical Trial of Anti-PD-1 in Hematologic Malignancy

Medical oncologist Alexander Lesokhin discusses a phase I dose escalation of an anti-PD-1 immunotherapy in patients with hematologic cancers.

Runtime: 03:00 minutes Published: 10/01/2012 - 8:42 AM

Clinical Trial: Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed AML

Hematologist-oncologist Ellin Berman discusses a randomized phase III clinical trial of an investigational oral drug, sapacitabine, for AML in elderly patients.

Runtime: 03:00 minutes Published: 05/01/2012 - 10:13 AM

Clinical Trial: BMS-906024 for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Hematologist-oncologist Don Douer discusses a Phase I clinical trial of intravenous BMS-906024.

Runtime: 02:00 minutes Published: 05/01/2012 - 10:03 AM

Integrated Genetic Profiling in Acute Myelogenous Leukemia

Mutational profiling can improve risk stratification and inform prognostic and therapeutic decisions regarding patients with AML.

Runtime: 03:00 minutes Published: 03/21/2012 - 3:26 PM

Late Relapses following ATRA for APL are Uncommon (2011 ASH Conference)

Leader of the Acute Lymphoblastic Leukemia Program Dan Douer discusses a study examining late relapses among APL patients.

Runtime: 02:00 minutes Published: 12/10/2011 - 9:36 AM

ASXL1 Mutations Promote Myeloid Transformation (2011 ASH Conference)

Medical oncologist Omar Abdel-Wahab discusses studies that assessed the functional implications of ASXL1 mutations in the hematopoietic compartment.

Runtime: 01:00 minutes Published: 12/10/2011 - 9:30 AM

SCI-33 Epigenetic Effects of IDH1/IDH2 Mutations (2011 ASH Conference)

Medical oncologist Omar Abdel-Wahab discusses data linking TET2 with the function of cytosine deaminases as a pathway toward DNA demethylation.

Runtime: 01:00 minutes Published: 12/10/2011 - 9:25 AM

Validation of a High-Risk MDS Prognostic Model (2011 ASH Conference)

Medical oncologist Omar Abdel-Wahab discusses a study that validates a lower-risk prognostic scoring system’s ability to identify higher-risk MDS patients.

Runtime: 01:00 minutes Published: 12/10/2011 - 9:04 AM

Arsenic Trioxide as Initial Therapy for Acute Promyelocytic Leukemia

Martin Tallman, a hematologist-oncologist at Memorial Sloan-Kettering, discusses a clinical trial combining arsenic trioxide with all-tansretinoic acid (ATRA) for the treatment of patients with APL.

Runtime: 3:00 minutes Published: 09/14/2011 - 12:00 AM